Share on StockTwits

Stock analysts at Barclays hoisted their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $173.00 to $182.00 in a report issued on Friday, AnalystRatings.Net reports. The firm currently has an “overweight” rating on the stock. Barclays’ target price suggests a potential upside of 7.18% from the stock’s previous close.

Shares of Celgene Corp. (NASDAQ:CELG) traded up 0.66% during mid-day trading on Friday, hitting $169.81. The stock had a trading volume of 2,793,909 shares. Celgene Corp. has a 52 week low of $95.37 and a 52 week high of $173.80. The stock’s 50-day moving average is $165.7 and its 200-day moving average is $149.2. The company has a market cap of $69.973 billion and a price-to-earnings ratio of 48.57.

Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, October 24th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $6.00 EPS for the current fiscal year.

CELG has been the subject of a number of other recent research reports. Analysts at Nomura initiated coverage on shares of Celgene Corp. in a research note to investors on Wednesday. They set a “buy” rating on the stock. Separately, analysts at UBS AG downgraded shares of Celgene Corp. from a “hold” rating to a “sell” rating in a research note to investors on Tuesday. Finally, analysts at Goldman Sachs Group Inc. downgraded shares of Celgene Corp. from a “neutral” rating to a “sell” rating in a research note to investors on Monday. They now have a $140.00 price target on the stock. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-two have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $163.44.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.